Combined treatment with lexatumumab and irradiation leads to strongly increased long term tumour control under normoxic and hypoxic conditions

Radiation Oncology

Volumn 4, Issue 1, 2009, Pages

  Marini, Patrizia ^a   Junginger, Dorothea ^a   Stickl, Stefan ^a   Budach, Wilfried ^c   Niyazi, Maximilian ^a   Belka, Claus ^a,b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

LEXATUMUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; RADIOSENSITIZING AGENT;

AMBIENT AIR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CONTROL; CANCER INHIBITION; CANCER RADIOTHERAPY; COLORECTAL CARCINOMA; CONTROLLED STUDY; HYPOXIA; MOUSE; NONHUMAN; NUDE MOUSE; RADIATION DOSE; TUMOR REGRESSION; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; CELL HYPOXIA; DRUG EFFECT; DRUG SCREENING; EXPERIMENTAL NEOPLASM; HUMAN; MULTIMODALITY CANCER THERAPY; RADIATION EXPOSURE; RADIATION RESPONSE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CELL HYPOXIA; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; RADIATION-SENSITIZING AGENTS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 71149095443     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-4-49     Document Type: Article

References (48)

1. Ashkenazi A, Holland P, Eckhardt SG. Ligand-based targeting of apoptosis in cancer: The potential of recombinant human apoptosis ligand 2/tumor necrosis factor-related apoptosis-inducing ligand (rhapo2l/trail). J Clin Oncol 2008, 26:3621-3630. 10.1200/JCO.2007.15.7198, 18640940.
2. Belka C, Schmid B, Marini P, Durand E, Rudner J, Faltin H, Bamberg M, Schulze-Osthoff K, Budach W. Sensitization of resistant lymphoma cells to irradiation-induced apoptosis by the death ligand trail. Oncogene 2001, 20:2190-2196. 10.1038/sj.onc.1204318, 11360204.
3. Marini P, Schmid A, Jendrossek V, Faltin H, Daniel PT, Budach W, Belka C. Irradiation specifically sensitises solid tumour cell lines to trail mediated apoptosis. BMC Cancer 2005, 5:5. 10.1186/1471-2407-5-5, 547906, 15651986.
4. Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J, Dixit VM. The receptor for the cytotoxic ligand trail. Science 1997, 276:111-113. 10.1126/science.276.5309.111, 9082980.
5. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin RG, Rauch CT, Schuh JC, Lynch DH. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999, 5:157-163. 10.1038/5517, 9930862.
6. Camidge DR. An agonist monoclonal antibody directed against death receptor 5/trail-receptor 2 for use in the treatment of solid tumors. Expert Opin Biol Ther 2008, 8:1167-1176. 10.1517/14712598.8.8.1167, 18613768.
7. Fiveash JB, Gillespie GY, Oliver PG, Zhou T, Belenky ML, Buchsbaum DJ. Enhancement of glioma radiotherapy and chemotherapy response with targeted antibody therapy against death receptor 5. Int J Radiat Oncol Biol Phys 2008, 71:507-516. 2750837, 18474311.
8. Humphreys R. HGS-TR2J, a human, agonistic, trail receptor-2 monoclonal antibody, induces apoptosis, tumor regression and growth inhibition as a single agent in diverse human solid tumor cell lines. Abstract #204.: 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. Genevre, Swiss 2004,
9. Ichikawa K, Liu W, Zhao L, Wang Z, Liu D, Ohtsuka T, Zhang H, Mountz JD, Koopman WJ, Kimberly RP, Zhou T. Tumoricidal activity of a novel anti-human dr5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med 2001, 7:954-960. 10.1038/91000, 11479629.
10. Marini P, Denzinger S, Schiller D, Kauder S, Welz S, Humphreys R, Daniel PT, Jendrossek V, Budach W, Belka C. Combined treatment of colorectal tumours with agonistic trail receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: Enhanced effects in vitro and dose-dependent growth delay in vivo. Oncogene 2006, 25:5145-5154.
11. Mom CH, Sleijfer S, Gietema JA, Fox NL, Piganeau C, Lo L, Uges DRA, Loos W, de Vries EGE, Verweij J. Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: A phase 1b study in patients with advanced solid malignancies. 2006, EORTC-NCI-AACR Prague, Czech Republic.
12. Motoki K, Mori E, Matsumoto A, Thomas M, Tomura T, Humphreys R, Albert V, Muto M, Yoshida H, Aoki M, Tamada T, Kuroki R, Yoshida H, Ishida I, Ware CF, Kataoka S. Enhanced apoptosis and tumor regression induced by a direct agonist antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2. Clin Cancer Res 2005, 11:3126-3135. 10.1158/1078-0432.CCR-04-1867, 15837769.
13. Pacey S, Plummer RE, Attard G, Bale C, Calvert AH, Blagden S, Fox NL, Corey A, de Bono JS. Phase I and pharmacokinetic study of HGS-ETR2, a human monoclonal antibody to TRAIL R2, in patients with advanced solid malignancies. J Clin Oncol 2005, 23:3055. abstr.
14. Saleh MN, Percent I, Wood TE, Posej J, Shah J, Carlisle R, Wojtowicz-Praga S, Forero-Torres A. A phase I study of CS-1008 (humanized monoclonal antibody targeting death receptor 5 or DR5), administered weekly to patients with advanced solid tumors or lymphomas.ASCO Annual meeting. Orlando, Florida, USA, . J Clin Oncol 2008, May 20 suppl; abstr 3537.
15. Sikic BI, Wakelee H, von Mehren M, Lewis NL, Plummer ER, Calvert AH, Fox NL, Kumm EA, Jones DF, Burris HA. A phase 1b study to assess the safety of lexatumumab, a human monoclonal antibody that activates TRAIL-R2, in combination with gemcitabine, pemetrexed, doxorubicin or FOLFIRI. Abstract, 2007. Proceedings of the American Society of Clinical Oncology 25:14006.
16. Tolcher AW, Mita M, Meropol NJ, von Mehren M, Patnaik A, Padavic K, Hill M, Mays T, McCoy T, Fox NL, Halpern W, Corey A, Cohen RB. Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J Clin Oncol 2007, 25:1390-1395. 10.1200/JCO.2006.08.8898, 17416859.
17. Vulfovich M, Saba N. Mapatumumab, human genome sciences/glaxosmithkline/takeda. Curr Opin Mol Ther 2005, 7:502-510.
18. Younes A, Vose JM, Zelenetz AD, Smith MR, Burris H, Ansell S, Klein J, Kumm E, Czuczman M. Results of a phase 2 trial of HGS-ETR1 (agonistic human monoclonal antibody to TRAIL receptor 1) in subjects with relapsed/refractory non-hodgkin's lymphoma (NHL). Blood 2005, 106:489. abstr.
19. Straughn JM, Oliver PG, Zhou T, Wang W, Alvarez RD, Grizzle WE, Buchsbaum DJ. Anti-tumor activity of tra-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model. Gynecol Oncol 2006, 101:46-54. 10.1016/j.ygyno.2005.09.053, 16271751.
20. Buchsbaum DJ, Zhou T, Grizzle WE, Oliver PG, Hammond CJ, Zhang S, Carpenter M, LoBuglio AF. Antitumor efficacy of tra-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model. Clin Cancer Res 2003, 9:3731-3741.
21. Marini P, Budach W, Niyazi M, Junginger D, Stickl S, Jendrossek V, Belka C. Combination of the pro-apoptotic trail-receptor antibody mapatumumab with ionizing radiation strongly increases long term tumor control under ambient and hypoxic conditions. Int J Radiat Oncol Biol Phys 2009, 75:198-202.
22. Baumann M, Krause M, Zips D, Eicheler W, Dorfler A, Ahrens J, Petersen C, Bruchner K, Hilberg F. Selective inhibition of the epidermal growth factor receptor tyrosine kinase by BIBX1382BS and the improvement of growth delay, but not local control, after fractionated irradiation in human fadu squamous cell carcinoma in the nude mouse. Int J Radiat Biol 2003, 79:547-559. 10.1080/0955300031000112839, 14530164.
23. Borst P, Borst J, Smets LA. Does resistance to apoptosis affect clinical response to antitumor drugs?. Drug Resist Updat 2001, 4:129-131. 10.1054/drup.2001.0187, 11512521.
24. Brown JM, Wouters BG. Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res 1999, 59:1391-1399.
25. Krause M, Prager J, Zhou X, Yaromina A, Dorfler A, Eicheler W, Baumann M. EGFR-TK inhibition before radiotherapy reduces tumour volume but does not improve local control: Differential response of cancer stem cells and nontumourigenic cells?. Radiother Oncol 2007, 83:316-325. 10.1016/j.radonc.2007.04.014, 17531334.
26. Schmitt CA, Lowe SW. Apoptosis is critical for drug response in vivo. Drug Resist Updat 2001, 4:132-134. 10.1054/drup.2001.0188, 11512522.
27. Harris AL. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2002, 2:38-47. 10.1038/nrc704, 11902584.
28. Walker AM, Suit HD. Assessment of local tumor control using censored tumor response data. Int J Radiat Oncol Biol Phys 1983, 9:383-386.
29. Shankar S, Singh TR, Chen X, Thakkar H, Firnin J, Srivastava RK. The sequential treatment with ionizing radiation followed by trail/apo-2l reduces tumor growth and induces apoptosis of breast tumor xenografts in nude mice. Int J Oncol 2004, 24:1133-1140.
30. Shankar S, Singh TR, Srivastava RK. Ionizing radiation enhances the therapeutic potential of trail in prostate cancer in vitro and in vivo: Intracellular mechanisms. Prostate 2004, 61:35-49. 10.1002/pros.20069, 15287092.
31. Douple EB, Richmond RC. Radiosensitization of hypoxic tumor cells by cis- and trans-dichlorodiammineplatinum (II). Int J Radiat Oncol Biol Phys 1979, 5:1369-1372.
32. Hoebers FJ, Pluim D, Verheij M, Balm AJ, Bartelink H, Schellens JH, Begg AC. Prediction of treatment outcome by cisplatin-DNA adduct formation in patients with stage III/IV head and neck squamous cell carcinoma, treated by concurrent cisplatin-radiation (radplat). Int J Cancer 2006, 119:750-756. 10.1002/ijc.21919, 16550603.
33. Chu G. Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair. J Biol Chem 1994, 269:787-790.
34. Dittmann K, Mayer C, Rodemann HP. Inhibition of radiation-induced egfr nuclear import by c225 (cetuximab) suppresses DNA-PK activity. Radiother Oncol 2005, 76:157-161. 10.1016/j.radonc.2005.06.022, 16024112.
35. Huang SM, Harari PM. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: Inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 2000, 6:2166-2174.
36. Suliman A, Lam A, Datta R, Srivastava RK. Intracellular mechanisms of trail: Apoptosis through mitochondrial-dependent and -independent pathways. Oncogene 2001, 20:2122-2133. 10.1038/sj.onc.1204282, 11360196.
37. Cuello M, Coats AO, Darko I, Ettenberg SA, Gardner GJ, Nau MM, Liu JR, Birrer MJ, Lipkowitz S. N-(4-hydroxyphenyl) retinamide (4HPR) enhances trail-mediated apoptosis through enhancement of a mitochondrial-dependent amplification loop in ovarian cancer cell lines. Cell Death Differ 2004, 11:527-541. 10.1038/sj.cdd.4401387, 14765134.
38. Belka C, Schmid B, Marini P, Durand E, Rudner J, Faltin H, Bamberg M, Schulze-Osthoff K, Budach W. Sensitization of resistant lymphoma cells to irradiation-induced apoptosis by the death ligand TRAIL. Oncogene 2001, 20:2190-2196. 10.1038/sj.onc.1204318, 11360204.
39. von Haefen C, Gillissen B, Hemmati PG, Wendt J, Guner D, Mrozek A, Belka C, Dorken B, Daniel PT. Multidomain Bcl-2 homolog bax but not Bak mediates synergistic induction of apoptosis by TRAIL and 5-FU through the mitochondrial apoptosis pathway. Oncogene 2004, 23:8320-8332. 10.1038/sj.onc.1207971, 15467752.
40. Deng Y, Lin Y, Wu X. TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of smac/diablo. Genes Dev 2002, 16:33-45. 10.1101/gad.949602, 155309, 11782443.
41. Griffith TS, Rauch CT, Smolak PJ, Waugh JY, Boiani N, Lynch DH, Smith CA, Goodwin RG, Kubin MZ. Functional analysis of TRAIL receptors using monoclonal antibodies. J Immunol 1999, 162:2597-2605.
42. Luciano F, Ricci JE, Herrant M, Bertolotto C, Mari B, Cousin JL, Auberger P. T and B leukemic cell lines exhibit different requirements for cell death: Correlation between caspase activation, dff40/dff45 expression, DNA fragmentation and apoptosis in T cell lines but not in Burkitt's lymphoma. Leukemia 2002, 16:700-707. 10.1038/sj.leu.2402401, 11960352.
43. Wu F, Hu Y, Long J, Zhou YJ, Zhong YH, Liao ZK, Liu SQ, Zhou FX, Zhou YF, Xie CH. Cytotoxicity and radiosensitization effect of TRA-8 on radioresistant human larynx squamous carcinoma cells. Oncol Rep 2009, 21:461-465. 10.3892/or_00000347, 19148523.
44. Weinmann M, Marini P, Jendrossek V, Betsch A, Goecke B, Budach W, Belka C. Influence of hypoxia on TRAIL-induced apoptosis in tumor cells. Int J Radiat Oncol Biol Phys 2004, 58:386-396.
45. Takahashi M, Inanami O, Kubota N, Tsujitani M, Yasui H, Ogura A, Kuwabara M. Enhancement of cell death by TNF alpha-related apoptosis-inducing ligand (TRAIL) in human lung carcinoma a549 cells exposed to x rays under hypoxia. J Radiat Res (Tokyo) 2007, 48:461-468. 10.1269/jrr.07028, 17895594.
46. Sturm I, Rau B, Schlag PM, Wust P, Hildebrandt B, Riess H, Hauptmann S, Dorken B, Daniel PT. Genetic dissection of apoptosis and cell cycle control in response of colorectal cancer treated with preoperative radiochemotherapy. BMC Cancer 2006, 6:124. 10.1186/1471-2407-6-124, 1525199, 16686938.
47. Mrozek A, Petrowsky H, Sturm I, Kraus J, Hermann S, Hauptmann S, Lorenz M, Dorken B, Daniel PT. Combined p53/Bax mutation results in extremely poor prognosis in gastric carcinoma with low microsatellite instability. Cell Death Differ 2003, 10:461-467. 10.1038/sj.cdd.4401193, 12719723.
48. Kallioniemi A. CGH microarrays and cancer. CurrOpin Biotechnol 2008, 19:36-40.